# Marco Vignetti

Source: https://onco.cc/people/marco-vignetti/  
OnCo record `marco-vignetti` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Haematologist who presides over GIMEMA, Italy's adult haematological malignancies cooperative group, and co-authored its chemotherapy-free Ph+ ALL trial.

## Summary

Marco Vignetti is President of Fondazione GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto), the Italian cooperative group that runs multicentre trials in adult haematological malignancies. He has co-authored landmark GIMEMA studies including the dasatinib-blinatumomab trial in Philadelphia-positive acute lymphoblastic leukaemia and the description of NPM1 mutations in normal-karyotype AML.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: leadership; clinician-scientist; leukaemia; clinical trials
- Role: President
- Specialisms: Haematology; Acute leukaemia; Clinical trials

## Sources

- Society page: https://www.gimema.it/organigramma/
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Vignetti+M%5BAuthor%5D

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- companies: [GIMEMA](https://onco.cc/companies/gimema/)

---
JSON: https://onco.cc/api/v1/entities/marco-vignetti.json